Alexion Pharmaceuticals, Inc. (ALXN) Formed a Bearish Multiple Bottom, Could Be One of The Worst Performers Going Forward

June 20, 2018 - By Mona Holcomb

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Logo

Investors sentiment decreased to 1 in 2018 Q1. Its down 0.03, from 1.03 in 2017Q4. It dropped, as 43 investors sold Alexion Pharmaceuticals, Inc. shares while 184 reduced holdings. 60 funds opened positions while 167 raised stakes. 200.94 million shares or 1.68% less from 204.38 million shares in 2017Q4 were reported.
Reliance Tru Of Delaware has 6,045 shares. De Burlo Gru Incorporated has invested 0.49% in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Rathbone Brothers Public Ltd Limited Liability Company holds 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) for 2,040 shares. Sentinel Trust Com Lba accumulated 70,920 shares. Verition Fund Mgmt Limited invested in 2,181 shares or 0.02% of the stock. Vanguard holds 0.07% or 15.37M shares. Mason Street Advsr Ltd Liability Corp holds 0.08% or 30,880 shares in its portfolio. Ameriprise Fincl has 0.38% invested in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN). Geode Management Limited Company, a Massachusetts-based fund reported 2.37 million shares. Bokf Na owns 2,390 shares. Citigroup reported 216,700 shares. Stephens Mgmt Grp Ltd holds 0.05% or 20,468 shares in its portfolio. Ubs Asset Americas, a Illinois-based fund reported 1.88 million shares. Comml Bank Of The West holds 0.49% or 35,236 shares. Apg Asset Mgmt Nv invested 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Since January 2, 2018, it had 1 buying transaction, and 16 selling transactions for $4.25 million activity. $707,048 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was sold by Clancy Paul J on Tuesday, February 6. 4,787 shares were sold by O’Neill Julie, worth $556,776 on Tuesday, February 6. The insider HANTSON LUDWIG sold $1.54 million. LAW ANNE-MARIE had sold 1,862 shares worth $220,703 on Friday, June 8. 1,645 shares were sold by Goff Brian, worth $194,982 on Friday, June 8. Another trade for 1,466 shares valued at $173,765 was made by Franchini Indrani Lall on Friday, June 8.

The stock of Alexion Pharmaceuticals, Inc. (ALXN) shows a multiple bottoms pattern with $115.81 target or 5.00 % below today’s $121.91 share price. The 9 months chart pattern indicates high risk for the $27.13B company. It was reported on Jun, 20 by Finviz.com. If the $115.81 price target is reached, the company will be worth $1.36B less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock increased 2.73% or $3.24 during the last trading session, reaching $121.91. About 1.15 million shares traded. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has risen 19.53% since June 20, 2017 and is uptrending. It has outperformed by 6.96% the S&P500.

Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on July, 26. They expect $1.47 earnings per share, up 12.21 % or $0.16 from last year’s $1.31 per share. ALXN’s profit will be $327.08M for 20.73 P/E if the $1.47 EPS becomes a reality. After $1.53 actual earnings per share reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -3.92 % negative EPS growth.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Ratings Coverage

Among 14 analysts covering Alexion Pharmaceuticals (NASDAQ:ALXN), 13 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Alexion Pharmaceuticals had 23 analyst reports since January 4, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, May 8 by Evercore. The rating was maintained by Stifel Nicolaus on Friday, April 27 with “Buy”. Piper Jaffray maintained the stock with “Buy” rating in Thursday, February 8 report. The firm has “Buy” rating by Nomura given on Monday, March 19. Stifel Nicolaus maintained Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Thursday, February 8 with “Buy” rating. Morgan Stanley maintained the shares of ALXN in report on Friday, February 9 with “Overweight” rating. Credit Suisse reinitiated the stock with “Outperform” rating in Thursday, January 18 report. The rating was maintained by SunTrust on Monday, February 12 with “Buy”. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Outperform” rating given on Thursday, January 4 by Raymond James. The company was maintained on Thursday, February 8 by BMO Capital Markets.

More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Streetinsider.com which released: “Alexion (ALXN)Says Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with PNH for Late-Breaking …” on June 14, 2018, also Bizjournals.com with their article: “Future home of PTC, Alexion could sell for $450M” published on June 20, 2018, Streetinsider.com published: “Alexion Pharma (ALXN) Submits Application for Priority Review and Approval of ALXN1210 as Treatment for Patients …” on June 19, 2018. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: 247Wallst.com and their article: “Short Sellers Up the Ante For Major Biotechs” published on June 12, 2018 as well as Investorplace.com‘s news article titled: “20 Nasdaq-100 Stocks That Will Heat Up 2H18” with publication date: June 15, 2018.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company has market cap of $27.13 billion. The firm offers Soliris , a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It has a 52.43 P/E ratio. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: